NCI-2021-11191

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of FWD1509 MsOH in Advanced Non-Small Cell Lung Cancer

This study is about testing a new treatment called FWD1509 MsOH for advanced non-small cell lung cancer. The study is looking at how safe and tolerable the treatment is, how the body processes it (pharmacokinetics), and how well it works against tumors. It is an open-label, Phase 1/2 study. The goal is to see if this new treatment can help patients with advanced lung cancer.

non-small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

pharmacokinetics: Pharmacokinetics studies how medicines move around in the body, including how they are absorbed, distributed, broken down, and removed.

Phase 1/2: A study that assesses the safety, effectiveness, and how well the treatment works

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05068024

Clinical Trial Site: Einstein

To see all available clinical trials click here.